Puma Biotechnology (NASDAQ:PBYI) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Valuation and Earnings

This table compares Puma Biotechnology and Oncolytics Biotech’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Puma Biotechnology $251.00 million 5.22 -$113.57 million ($2.99) -11.39
Oncolytics Biotech N/A N/A -$13.14 million ($0.82) -2.32

Oncolytics Biotech has lower revenue, but higher earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Puma Biotechnology has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Puma Biotechnology and Oncolytics Biotech, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Puma Biotechnology 3 5 4 0 2.08
Oncolytics Biotech 0 0 2 0 3.00

Puma Biotechnology presently has a consensus target price of $52.20, suggesting a potential upside of 53.26%. Given Puma Biotechnology’s higher probable upside, equities research analysts plainly believe Puma Biotechnology is more favorable than Oncolytics Biotech.

Insider & Institutional Ownership

91.9% of Puma Biotechnology shares are held by institutional investors. Comparatively, 0.9% of Oncolytics Biotech shares are held by institutional investors. 21.5% of Puma Biotechnology shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


This table compares Puma Biotechnology and Oncolytics Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Puma Biotechnology -45.22% -258.02% -51.18%
Oncolytics Biotech N/A -219.88% -100.15%


Oncolytics Biotech beats Puma Biotechnology on 7 of the 13 factors compared between the two stocks.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.